Protocol Ledger

NCT05498428 · Phase II · RECRUITING

A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer

Interventional Phase II clinical trial protocol NCT05498428 sponsored by Johnson & Johnson / Janssen in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2022-11-11 Enrollment: 520 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT05498428
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)520 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05498428
Protocol FieldVerified Registry Value
NCT IdentifierNCT05498428
Consolidated Lead SponsorJohnson & Johnson / Janssen
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment520 participants (ESTIMATED)
Registered Start Date2022-11-11
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Johnson & Johnson across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI